<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88902">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01730352</url>
  </required_header>
  <id_info>
    <org_study_id>08/56706-0</org_study_id>
    <nct_id>NCT01730352</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients</brief_title>
  <official_title>Helicobacter Pylori Infection and Chronic Immune Thrombocytopenic Purpura in Children and Adolescents - A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <authority>Brazil: Agencia Nacional de Vigilancia Sanitaria (ANVISA)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether eradication of Helicobacter pylori
      infection is effective in the improvement of platelet counts in children and adolescents
      with chronic ITP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori infection has been associated with Immune Thrombocytopenic Purpura
      (ITP), and there is scientific evidence for the investigation and treatment of this
      bacterium for adult patients with ITP. However, in children this causal association is not
      clear, with few published studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>platelet response</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Responders: Complete Response (CR), persistent elevation of platelet count to &gt;150×109/L; Partial Response (PR), elevation between 20 and 30×109/L above the baseline values, but between 50 and 149×109/L; No Responders: any of the above categories.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Immune Thrombocytopenic Purpura</condition>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>H. pylori no treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observational group, with clinical and platelet count follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H. pylori triple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triple therapy for H. pylori eradication: clarithromycin 15mg/kg, amoxicillin 50mg/kg, furazolidone 7mg/kg and/ or doxycycline 4,4mg/kg (all 2 times per day), with a proton pump inhibitor for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H. pylori triple therapy</intervention_name>
    <description>Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.</description>
    <arm_group_label>H. pylori triple therapy</arm_group_label>
    <other_name>Triple therapy for H. pylori</other_name>
    <other_name>H. pylori eradication therapy</other_name>
    <other_name>Pyloripac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of chronic immune thrombocytopenic purpura

          -  children and adolescents up to 20 years

        Exclusion Criteria:

          -  known hypersensitivity to any of the drugs

          -  recent treatment for H. pylori eradication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabete Kawakami, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federal University of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04021-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Hematologia de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01401-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual Infantil Darcy Vargas</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05614-040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericordia se Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01221-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 20, 2012</lastchanged_date>
  <firstreceived_date>November 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Elisabete Kawakami</investigator_full_name>
    <investigator_title>Professor, PhD MD</investigator_title>
  </responsible_party>
  <keyword>immune thrombocytopenic purpura</keyword>
  <keyword>chronic immune thrombocytopenic purpura</keyword>
  <keyword>secondary immune thrombocytopenic purpura</keyword>
  <keyword>Helicobacter pylori infection</keyword>
  <keyword>Helicobacter pylori gastritis</keyword>
  <keyword>children</keyword>
  <keyword>adolescents</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Purpura</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
